<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364466">
  <stage>Registered</stage>
  <submitdate>20/06/2013</submitdate>
  <approvaldate>26/06/2013</approvaldate>
  <actrnumber>ACTRN12613000699763</actrnumber>
  <trial_identification>
    <studytitle>Nicotinamide and innate immunity in patients with bronchiectasis</studytitle>
    <scientifictitle>Enhanced innate immunity and killing of respiratory pathogens by nicotinamide in patients with bronchiectasis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NONE</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Bronchiectasis</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants will take oral nicotinamide capsules twice daily in one of the 4 dosage groups for a total duration of 2 weeks:- 1500mg twice daily
              2000mg twice daily
              2500mg twice daily 
              3000mg twice daily
compliance will be ensured by capsules count at every follow up visit, blood will be collected for nicotinamide level prior to start of nicotinamide taking and then at every follow up visit.</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Dose of nicotinamide required to achieve serum level of 1 mM, this will be assessed by collecting blood samples for serum nicotinamide level analysis at each follow up visits from visit 2 to visit 5</outcome>
      <timepoint>two weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Counts of surviving bacterial colony-forming units after inoculation of the pathogen with nicotinamide treated blood</outcome>
      <timepoint>two weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum Level of C/EBPe expression </outcome>
      <timepoint>two weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>serum lactoferrin level</outcome>
      <timepoint>two weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>serum cathelicidin level</outcome>
      <timepoint>two weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Male or female aged between 18 to 80 years old
- able to provide written consent form
- Patients with confirmed bronchiectasis by High resolution
  CT scan
- history of at least one pulmonary exacerbation in the 
  past 12 months
- healthy volunteers should be never smoker with no
  underlying acute or chronic medical conditions and not
  taking regular medications
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- Pregnant or lactating women
- patients with significant medical conditions other than 
  bronchiectasis
- patients with significant abnormal liver function or with 
  liver cirrhosis
- patients with a history of non-adherence with medications

</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Other</assignment>
    <designfeatures>One volunteer and one bronchiectasis patient will be allocated to each of the 4 dosing groups by sequence.</designfeatures>
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods>The primary outcome nicotinamide levels will be described and analysed at baseline, 48hours, 1 week and 2 weeks.
Descriptives will be produced for all other study outcomes at each time point. </statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/07/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>8</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Dr Conroy Wong, Middlemore Hospital</primarysponsorname>
    <primarysponsoraddress>Middlemore Hospital
Private Bag 93311
Otahuhu
Auckland 1640
New Zealand</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Respiratory Research Fund, Middlemore Hospital</fundingname>
      <fundingaddress>Middlemore Hospital
Private Bag 93311
Otahuhu
Auckland 1640
New Zealand
</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Charities/Societies/Foundations</sponsortype>
      <sponsorname>Centre for Clinical Research and effective practice</sponsorname>
      <sponsoraddress>Centre for Clinical Research and effective practice
Private Bag 93311
Otahuhu
Auckland 1640</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We aim to determine the dose of nicotinamide (NAM) that achieves a serum level of at least 1 mM, and also to assess the effect of nicotinamide on upregulation of neutrophil function and bacterial killing in both patients with bronchiectasis and healthy volunteers.

We want to prove if nicotinamide may augment neutrophil function and enhance the killing of respiratory pathogens in patients with bronchiectasis</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern A Health and Disability Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
1 the Terrace
PO Box 5013
Wellington
6011</ethicaddress>
      <ethicapprovaldate>15/03/2013</ethicapprovaldate>
      <hrec>13/NTA/28</hrec>
      <ethicsubmitdate>26/02/2013</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Conroy Wong</name>
      <address>Respiratory Services
Middlemore Hospital
Private bag 93311
Otahuhu
Auckland 1640
New Zealand</address>
      <phone>+64 9 276 0000</phone>
      <fax>+64 9 270 9737</fax>
      <email>Conroy.Wong@middlemore.co.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Cecilia Tong</name>
      <address>Centre for Clinical Research and effective practice
Private bag 93311
Otahuhu
Auckland 1640
New Zealand</address>
      <phone>+64 9 276 0000</phone>
      <fax>+64 9 270 9737</fax>
      <email>Cecilia.Tong@ccrep.org.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Conroy Wong</name>
      <address>Respiratory Services
Middlemore Hospital
Private bag 93311
Otahuhu
Auckland 1640
New Zealand</address>
      <phone>+64 9 276 0000</phone>
      <fax>+64 9 270 9737</fax>
      <email>Conroy.Wong@middlemore.co.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Cecilia Tong</name>
      <address>Centre for Clinical Research and effective practice
Private bag 93311
Otahuhu
Auckland 1640
New Zealand</address>
      <phone>0064 9 276 0000</phone>
      <fax>0064 9 270 9737</fax>
      <email>Cecilia.Tong@ccrep.org.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>